logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

RegenxBio Has Good News

RegenxBio License Agreement with Pfizer RegenxBio ( RGNX )   announced a license agreement with  Pfizer ( PFE ). Under the terms of the agreement RegenxBio has granted Pfizer a non-exclusive worldwide license, with rights to sublicense, to RegenxBio's NAV...

Read More

August 1, 2019

0

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

Rhythm Pharmaceuticals, Inc. (RYTM) is a biopharmaceutical company focused on the development and commercialization of therapeutics for rare genetic disorders of obesity . It is currently evaluating the efficacy and safety of setmelanotide , the company’s first-in-class MC4R agonist in Phase...

Read More

January 4, 2019

0

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News Story

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals ( RYTM )   we learned that positive, top-line results from two pivotal Phase 3 clinical trials evaluating setmelanotide,   for pro-opiomelanocortin ( POMC ) and leptin receptor ( LEPR ) deficiency obesities, have met...

Read More

August 7, 2019

0

The importance of the FDA granting Fast Track Designation to Vertex's and CRISPR's Product CTX-001

Earlier this month the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CTX001 for sickle cell disease (SCD). CTX001 is in clinical trials conducted by CRISPR Therapeutics (CRSP)   and  Vertex Pharmaceuticals (VRTX) . It is an investigational, autologous,...

Read More

January 7, 2019

0

Why the new approval of Exelixis' blood pressure drug Minnebro in Japan is important

Exelixis collaborator, Daiichi Sankyo, Receives Regulatory Approval for MINNEBRO™ (Esaxerenone) Tablets for Hypertension in Japan Exelixis (EXEL)   and  Daiichi Sankyo  announced that the the Japanese Ministry of Health, Labor and Welfare  (MHLW) has approved Minnebro™ ( esaxerenone) tablets of ,1.25...

Read More

January 9, 2019

0

More Exciting News for Sangamo

Sangamo’s (SGMO)  has abundant positive news since it offered proof of concept and feasibility of its zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation approach and other approaches. The most recent announcement was made early today by Sangamo and  Pfizer...

Read More

January 3, 2018

0

Another drug approval for Exelixis. Why Alnylam's stock is under pressure today

More good news came  from Exelixis (EXEL) . It  was expected by many but not by those who ignore the good news in favor of any negative news or lack of news. The announced news is that the FDA approved Exelixis’...

Read More

January 15, 2019

0

Exelixis Strategy: Expanding the Pipeline with Novel Products

As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and cobimetinib,   Exelixis (EXEL)   entered into an exclusive collaboration and license agreement with  StemSynergy Therapeutics .  The aim of...

Read More

January 8, 2018

0

Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer

Juno Therapeutics’ (JUNO)   stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street journal report stating that Celgene (CELG) was in discussions to take over Juno and that the negotiations could result in a deal...

Read More

January 17, 2018

0

Why Amgen's Stock Is Up Over $11 Today

Amgen's Stock Is Up Amgen ( AMGN )   is speeding towards reaching its true, fair value. In the Q2 financial results Amgen has beaten the most optimistic analysts’ expectations and negative investors who keep mourning the firm’s 35 years...

Read More

August 9, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 62
  • 63
  • 64
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy